| | 163222-33-1 Basic information More.. |
| Product Name: | Ezetimibe | | Synonyms: | (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one;Ezetimibe-001;Ticagrelor and its interMediate;Ezetimibe
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one;Ezatimibe;zetia/vytorin;SCH 60969;Ezetimibe, >=99% | | CAS: | 163222-33-1 | | MF: | C24H21F2NO3 | | MW: | 409.43 | | EINECS: | 682-606-0 | | Mol File: | 163222-33-1.mol |  |
Use
Ezetimibe was approved as the first hypolipidemic drug to act by blocking the absorption of dietary cholesterol. Ezetimibe is indicated as monotherapy or in combination with an HMGRI for the reduction of elevated total cholesterol, LDL cholesterol, and apoB in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia.
- Ezetimibe
-
- 2026-02-25
- CAS:163222-33-1
- Min. Order:
- Purity: 0.99
- Supply Ability:
- Ezetimibe
-
- US $41.00-70.00 / mg
- 2026-02-25
- CAS:163222-33-1
- Min. Order:
- Purity: 97.28%
- Supply Ability: 10g
- Ezetimibe
-
- US $65.00-60.00 / kg
- 2026-02-25
- CAS:163222-33-1
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20Tons
|
|
163222-33-1
Recommend Suppliers |
|